Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635639 | 0.94 | SYK (0.46) | SYKJAK3JAK2CYP2C9LMNA | |
| SCHEMBL2274537 | 0.81 | SYK (0.48) | SYKJAK3JAK2ADORA3ADORA1 | |
| SCHEMBL2280589 | 0.80 | SYK (0.71) | SYKJAK3JAK2CYP2C9GAA | |
| SCHEMBL2280574 | 0.79 | MAPK1 (0.50) | SYKJAK3JAK2CYP2C9MAPK1 | |
| SCHEMBL2275777 | 0.78 | LDHB (0.50) | SYKJAK3JAK2CYP2C9MAPK1 | |
| SCHEMBL2282266 | 0.77 | CDK8 (0.47) | SYKJAK3JAK2CYP2C9MAPK1 | |
| SCHEMBL2279424 | 0.76 | JAK3 (0.51) | SYKJAK3JAK2CYP2C9MAPK1 | |
| SCHEMBL2276900 | 0.76 | JAK3 (0.44) | SYKJAK3JAK2CYP2C9MAPK1 | |
| SCHEMBL2278382 | 0.76 | SYK (0.74) | SYKJAK3JAK2CYP2C9 | |
| SCHEMBL14575808 | 0.75 | GLA (0.49) | SYKLMNAKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | claimed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | claimed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | claimed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | claimed |
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | SYK 1/4885JAK3 7/4885JAK2 4/4885 |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK1 | SYK 1/4885JAK3 7/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.